Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
UNCY 
Unicycive Therapeutics Inc (UNCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: UNCY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $50.62
1 Year Target Price $50.62
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.69% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.07M USD | Price to earnings Ratio - | 1Y Target Price 50.62 |
Price to earnings Ratio - | 1Y Target Price 50.62 | ||
Volume (30-day avg) 7 | Beta 1.86 | 52 Weeks Range 3.71 - 11.00 | Updated Date 10/17/2025 |
52 Weeks Range 3.71 - 11.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51% | Return on Equity (TTM) -131.87% |
Valuation
Trailing PE - | Forward PE 1.25 | Enterprise Value 59746044 | Price to Sales(TTM) 23.75 |
Enterprise Value 59746044 | Price to Sales(TTM) 23.75 | ||
Enterprise Value to Revenue 16.63 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 17661698 | Shares Floating 13007664 |
Shares Outstanding 17661698 | Shares Floating 13007664 | ||
Percent Insiders 3.56 | Percent Institutions 30.5 |
Upturn AI SWOT
Unicycive Therapeutics Inc
Company Overview
History and Background
Unicycive Therapeutics Inc. (UNCY) is a biopharmaceutical company focused on developing and commercializing novel therapies for kidney diseases. Founded to address unmet needs in renal care, they aim to improve the lives of patients with kidney-related disorders. Specific founding year details and early milestones are not readily available in common public sources.
Core Business Areas
- Renal Disease Therapies: Development and commercialization of therapies targeting acute kidney injury, chronic kidney disease, and other renal disorders.
Leadership and Structure
Details on the specific leadership team and organizational structure are best sourced directly from Unicycive's investor relations website. Typically includes a CEO, CFO, CMO, and a board of directors.
Top Products and Market Share
Key Offerings
- Renazorb: Renazorb is Unicyciveu2019s lead product candidate, an oral formulation of lanthanum carbonate, designed to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. While specific market share data is not publicly available for Renazorb as it's in development, competitors include Sanofi's Renvela and Shire's Fosrenol. The TAM for hyperphosphatemia treatments is significant due to the high prevalence of CKD.
- Losartan: Losartan is an angiotensin II receptor blocker (ARB) that's used to treat high blood pressure and protect the kidneys. Unicycive is formulating a novel treatment that consists of Losartan to protect from various ailments, primarily kidney disease. Specific market share data is not publicly available for the Unicycive proprietary formula as it's in development. Competitors include Teva's Losartan Potassium tablets and Novartis' Cozaar. The TAM for Losartan and Losartan based treatments is significant due to high prevalance of these issues, but Losartan is a generic treatment
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and heavily regulated. Demand for kidney disease treatments is increasing due to the aging population and rising prevalence of diabetes and hypertension.
Positioning
Unicycive focuses on addressing unmet needs in the renal space. Its competitive advantage lies in developing novel formulations and targeting specific patient populations within the kidney disease market.
Total Addressable Market (TAM)
The global kidney disease therapeutics market is estimated to be in the billions of dollars. Unicycive aims to capture a portion of this market through its innovative therapies, particularly Renazorb. Positioned to address a significant unmet need in the hyperphosphatemia treatment market.
Upturn SWOT Analysis
Strengths
- Novel drug development pipeline
- Focus on unmet needs in renal care
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Limited market presence
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new renal disease indications
- Regulatory approval and commercialization of Renazorb
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles and changes in healthcare policies
Competitors and Market Share
Key Competitors
- SNY
- VTRS
- KDP
Competitive Landscape
Unicycive faces intense competition from established pharmaceutical giants. Its success hinges on the successful development and commercialization of its novel therapies and securing strategic partnerships. UNCY is the smallest competitor mentioned and as such must work diligently to stay afloat against its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are best evaluated by analyzing past financial performance.
Future Projections: Future projections are based on analyst estimates and company guidance.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials, regulatory submissions, and partnerships.
Summary
Unicycive Therapeutics Inc. is a biopharmaceutical company focused on renal disease therapies. The company's strength lies in its novel drug development pipeline, particularly Renazorb. However, it faces weaknesses due to limited financial resources and reliance on clinical trial success. The company needs to capitalize on partnerships and achieve regulatory approvals to compete effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Providers
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and financial data are estimates based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Unicycive Therapeutics Inc
Exchange NASDAQ | Headquaters Los Altos, CA, United States | ||
IPO Launch date 2021-07-12 | Founder, Chairman, CEO & President Dr. Shalabh K. Gupta M.D., MPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://unicycive.com |
Full time employees 22 | Website https://unicycive.com | ||
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.